JP2022533971A5 - - Google Patents

Info

Publication number
JP2022533971A5
JP2022533971A5 JP2021568611A JP2021568611A JP2022533971A5 JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5 JP 2021568611 A JP2021568611 A JP 2021568611A JP 2021568611 A JP2021568611 A JP 2021568611A JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032941 external-priority patent/WO2020232274A1/en
Publication of JP2022533971A publication Critical patent/JP2022533971A/ja
Publication of JP2022533971A5 publication Critical patent/JP2022533971A5/ja
Priority to JP2025062046A priority Critical patent/JP2025114555A/ja
Pending legal-status Critical Current

Links

JP2021568611A 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤 Pending JP2022533971A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062046A JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848420P 2019-05-15 2019-05-15
US62/848,420 2019-05-15
PCT/US2020/032941 WO2020232274A1 (en) 2019-05-15 2020-05-14 Ketamine formulation for subcutaneous injection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062046A Division JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Publications (2)

Publication Number Publication Date
JP2022533971A JP2022533971A (ja) 2022-07-27
JP2022533971A5 true JP2022533971A5 (OSRAM) 2023-05-23

Family

ID=73230954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Country Status (6)

Country Link
US (2) US10973780B2 (OSRAM)
EP (1) EP3968979A4 (OSRAM)
JP (2) JP2022533971A (OSRAM)
CN (2) CN114126596A (OSRAM)
CA (1) CA3140046A1 (OSRAM)
WO (1) WO2020232274A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020232274A1 (en) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
IL300547A (en) 2020-08-18 2023-04-01 Oakwood Laboratories LLC Microsphere formulations comprising ketamine and methods for their production and use
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
WO2022109050A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
JP2025509517A (ja) * 2022-03-14 2025-04-11 パーセプション ニューロサイエンス，インコーポレイティド Ｒ－ケタミンの医薬製剤
US20250345458A1 (en) * 2022-05-18 2025-11-13 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
IN202221054235A (OSRAM) 2022-09-22 2023-11-03
WO2024171074A1 (en) * 2023-02-15 2024-08-22 Clearmind Medicine Inc. Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング　コーポレイション 医薬組成物
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
CN101765582A (zh) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
CN104395283A (zh) * 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20130296437A1 (en) 2012-05-04 2013-11-07 E-Therapeutics Plc Treatment of Depression
US10124940B2 (en) 2012-09-11 2018-11-13 Zolo Solutions, Inc. Systems, methods, and devices for dispensing one or more substances
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2020232274A1 (en) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection

Similar Documents

Publication Publication Date Title
JP2025114555A5 (OSRAM)
KR810000900B1 (ko) 항생물질 조성제의 안정화 방법
US20040209843A1 (en) Aqueous cilostazol preparation for injection
CN114126596A (zh) 用于皮下注射的氯胺酮制剂
JP3933683B2 (ja) アジスロマイシン含有水性医薬組成物及びその調製方法
US11382927B2 (en) Liquid medicinal preparation
TWI538673B (zh) 包含撲熱息痛的醫藥組成物及其製備方法
JP7110196B2 (ja) カルバメート化合物を含む非経口用液剤
EP2934593B1 (en) Cabazitaxel composition
CN114746092A (zh) D-苯丙胺化合物、组合物、以及制备和使用它们的方法
KR20100051694A (ko) 주사제, 주사 용액, 및 주사 키트 제제
CN1812794B (zh) 溶液药用组合物
JP7090845B2 (ja) パロノセトロン含有液体組成物
JP7267640B2 (ja) 希釈安定性に優れたテニポシド注射用溶液及びその調製方法
CA3046458C (en) Parenteral liquid preparation comprising carbamate compound
EP1682149B1 (en) Injectable gabapentin compositions
KR20250020129A (ko) 고농도의 아포모르핀을 포함하는 수성 배합물 및 그의 용도
US20040019013A1 (en) Formulation for the parenteral application of a sodium channel blocker
HK40078104A (en) D-amphetamine compounds, compositions, and processes for making and using the same
HK40063844B (zh) 一种药物组合物及其应用
JP2000119177A (ja) 鎮痛剤
HK40015062A (en) Parenteral liquid preparation comprising carbamate compound
WO2018109731A1 (en) Pharmaceutical compositions of taxane and its derivatives
JP2005531573A (ja) クロベネチンの非経口的用途用の新規製剤
JPWO2016175092A1 (ja) 肝細胞癌の予防又は治療のための医薬